|
20 Companies |
|
37 Products |
|
37 Products |
|
44 Mechanisms of Action |
|
0 Trials |
|
115 News |
|
| 123» |
- | acetylcysteine solution / Generic mfg.
Trial completion, Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 30, 2019
P2, N=34, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018
- | Trial completion, Phase classification, Metastases: MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 23, 2019
P=N/A, N=3, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 Recruiting --> Completed | Phase classification: P1 --> PN/A
- | acetylcysteine solution / Generic mfg.
Enrollment change, Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 19, 2019
P2, N=34, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | Phase classification: P1 --> PN/A N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination, Metastases: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer (clinicaltrials.gov) - Jan 18, 2019
P1, N=19, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019 Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision.
- | acetylcysteine solution / Generic mfg.
Phase classification: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Oct 31, 2018
P2, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Phase classification: P=N/A --> P2
- | dasatinib / Generic mfg.
Trial completion, Metastases: Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors (clinicaltrials.gov) - Apr 20, 2018
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P2 Active, not recruiting --> Completed
- | MK-2206 / Merck (MSD)
Trial completion, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | acetylcysteine solution / Generic mfg.
Trial completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Dec 2018
- | doxepin / Generic mfg.
Trial completion: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Aug 9, 2017
P3, N=155, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed
- | docetaxel / Generic mfg.
Trial completion, Trial primary completion date: Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=69, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2013
- | Herceptin (trastuzumab) / Roche
Trial completion, Trial initiation date: Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer (clinicaltrials.gov) - Apr 18, 2017
P2, N=14, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2013 Active, not recruiting --> Completed | Initiation date: Jan 1999 --> Oct 1999
- oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Trial termination, Metastases: Title XELOX FOR SALIVARY GLAND CANCERS (clinicaltrials.gov) - Feb 27, 2017
P2, N=9, Terminated, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Initiation date: Jan 1999 --> Oct 1999 N=33 --> 9 | Active, not recruiting --> Terminated; Slow Accrual
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
N=33 --> 9 | Active, not recruiting --> Terminated; Slow Accrual Active, not recruiting --> Completed
- brontictuzumab (OMP-52M51) / Mereo Biopharma
Trial completion, Trial primary completion date: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=1, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016
- gemcitabine / Generic mfg.
Trial completion, Enrollment change, Surgery, Metastases: Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery (clinicaltrials.gov) - Jan 19, 2017
P2, N=16, Completed, Sponsor: Dana-Farber Cancer Institute
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2016 --> Mar 2016 Active, not recruiting --> Completed | N=60 --> 16
- | fluconazole oral / Generic mfg.
Trial completion: Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Dec 14, 2016
P2/3, N=0, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed | N=60 --> 16 Not yet recruiting --> Completed
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Enrollment change, Metastases: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma (clinicaltrials.gov) - Oct 27, 2016
P2, N=36, Completed, Sponsor: University of Virginia
Not yet recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 36
- | Inlyta (axitinib) / Pfizer
Trial completion, Trial primary completion date, IO biomarker, Metastases: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma (clinicaltrials.gov) - Aug 19, 2016
P2, N=33, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=10 --> 36 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2016
- | docetaxel / Generic mfg.
Trial completion: Docetaxel in Treating Patients With Solid Tumors (clinicaltrials.gov) - Jul 12, 2016
P2, N=109, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2016 Active, not recruiting --> Completed
- Inlyta (axitinib) / Pfizer
Trial primary completion date, IO biomarker, Metastases: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma (clinicaltrials.gov) - May 3, 2016
P2, N=32, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Mar 2017
- acetylcysteine solution / Generic mfg.
Enrollment closed, Enrollment change: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=18, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting | N=36 --> 18
- brontictuzumab (OMP-52M51) / Mereo Biopharma
New trial: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=1, Enrolling by invitation, Sponsor: M.D. Anderson Cancer Center
- Trial completion, HEOR: Head & Neck Cancer Survivorship: Physical and Functional Status (clinicaltrials.gov) - Dec 12, 2015
P1, N=23, Completed, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | N=36 --> 18 Active, not recruiting --> Completed
- pemetrexed / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2015
P1, N=33, Completed, Sponsor: University of Arizona
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014
- | Trial completion, Adverse events, Metastases: Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Oct 16, 2015
P=N/A, N=20, Completed, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- NN1213 / Novo Nordisk
Trial completion: Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=434, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Sep 17, 2015
P2, N=21, Completed, Sponsor: Ontario Clinical Oncology Group (OCOG)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Trial completion, Enrollment change, Metastases: A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Aug 12, 2015
P2, N=14, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 14
- docetaxel / Generic mfg.
Trial initiation date, Trial primary completion date: Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=69, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=25 --> 14 Initiation date: Feb 2009 --> Oct 2008 | Trial primary completion date: May 2010 --> Jan 2100
- acetylcysteine solution / Generic mfg.
Trial primary completion date: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
Initiation date: Feb 2009 --> Oct 2008 | Trial primary completion date: May 2010 --> Jan 2100 Trial primary completion date: Apr 2015 --> Apr 2018
- dovitinib (TKI258) / Novartis, Oncoheroes
Trial primary completion date, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Jun 11, 2015
P2, N=21, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial primary completion date: Apr 2015 --> Apr 2018 Trial primary completion date: Jul 2014 --> Jul 2015
- | everolimus / Generic mfg.
Trial completion, Monotherapy: ACCRAD001: Study of RAD001 in Adenoid Cystic Carcinoma (clinicaltrials.gov) - May 20, 2015
P2, N=33, Completed, Sponsor: Seoul National University Hospital
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Completed
- Inlyta (axitinib) / Pfizer
Trial primary completion date, IO biomarker, Metastases: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma (clinicaltrials.gov) - Apr 30, 2015
P2, N=32, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Trial primary completion date: Mar 2015 --> Mar 2016
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Mar 2016 No longer recruiting --> Completed
- | Trial completion, Enrollment change: Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract (clinicaltrials.gov) - Feb 10, 2015
P3, N=311, Completed, Sponsor: Centre Antoine Lacassagne
No longer recruiting --> Completed Recruiting --> Completed | N=420 --> 311
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Trial primary completion date, Monotherapy: Dovitinib in Adenoid Cystic Carcinoma (clinicaltrials.gov) - Nov 13, 2014
P2, N=33, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed | N=420 --> 311 Recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2013
- Enrollment change, Trial termination, Trial primary completion date, Surgery: Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=7, Terminated, Sponsor: City of Hope Medical Center
Recruiting --> Completed | Trial primary completion date: Sep 2013 --> Dec 2013 N=30 --> 7 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Nov 2014; The study will be rewritten as a data registry study
- Trial primary completion date, Surgery: Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=30, Recruiting, Sponsor: City of Hope Medical Center
N=30 --> 7 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Nov 2014; The study will be rewritten as a data registry study Trial primary completion date: Nov 2016 --> Mar 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2016 --> Mar 2017 Phase classification: P1/2 --> P1
- Inlyta (axitinib) / Pfizer
Trial primary completion date, IO biomarker, Metastases: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=32, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Phase classification: P1/2 --> P1 Trial primary completion date: Mar 2014 --> Mar 2015
- Enrollment closed, Trial primary completion date, Surgery, Metastases: Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jul 23, 2014
P1, N=30, Active, not recruiting, Sponsor: Boston Medical Center
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Dec 2014
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Jul 14, 2014
P2, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2013 --> Dec 2014 N=15 --> 18
- Trial withdrawal: Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
N=15 --> 18 Terminated --> Withdrawn
- Enrollment change, Trial withdrawal: Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Terminated --> Withdrawn N=50 --> 0 | Terminated --> Withdrawn
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 0 | Terminated --> Withdrawn Trial primary completion date: Jul 2008 --> Oct 2007
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2008 --> Oct 2007 Recruiting --> Completed
- | doxepin / Generic mfg.
Enrollment closed: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - May 13, 2014
P3, N=162, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Enrollment open: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Clinical: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic